Xbiome

Xbiome is **China's leading AI-driven microbiome drug development company** founded in 2017. The company is dedicated to gut microbiome using AI techniques and is committed to the gut health of human beings with medical treatments and precise and personalized management. The gut, being the largest microbial ecosystem in the human body, hosts about 100 trillion microbes – 500 – 1000 unique species and contains 150-fold more genes than the human genome, which systematically influence human health. More than 50 human diseases are associated with dysbiosis of gut microbiota. Xbiome's innovative approach combines microbial technologies, artificial intelligence, bioinformatics analysis, and gut microbiome technologies into a unique drug development platform, which substantially speeds up and improves the success rate of new drug development. The company's headquarters is located in **the United States**. Xbiome recently secured a significant **$100.00M Series B investment on 22 December 2021**. The investment was made by a group of prominent investors, including **Gaorong Capital, Sky9 Capital, Legend Capital, 5Y Capital, Hike Capital, Primavera Capital, Wuyuan Capital, and Tiantu Capital**. Xbiome operates in the AI, biotechnology, and pharmaceutical industries.